All Bacillus Calmette-Guérin (BCG) Strains Are Equal, but Some BCG Strains Are More Equal Than Others
- 1 October 2014
- journal article
- Published by Elsevier BV in European Urology
- Vol. 66 (4), 689-691
- https://doi.org/10.1016/j.eururo.2014.04.008
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer ImmunotherapyEuropean Urology, 2014
- BCG immunotherapy for bladder cancer—the effects of substrain differencesNature Reviews Urology, 2013
- A Prospective Comparative Study of Intravesical Bacillus Calmette-Guérin Therapy with the Tokyo or Connaught Strain for Nonmuscle Invasive Bladder CancerJournal of Urology, 2013
- Challenging current paradigmsNature Reviews Urology, 2013
- Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparisonUrology Annals, 2013
- BACILLUS CALMETTE-GUERIN TOKYO172 SUBSTRAIN FOR SUPERFICIAL BLADDER CANCER: CHARACTERIZATION AND ANTITUMOR EFFECTJournal of Urology, 2005
- Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the BladderJournal of Urology, 1995
- Marker tumour response to Evans and Pasteur bacilie Calmette‐Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)BJU International, 1994
- Intravesical BCG Treatment for Superficial Bladder Cancer: Long‐term Results using Two Different Strains of BCGBJU International, 1992
- Intravesical BCG Therapy in the Management of Multiple Superficial Bladder Carcinoma Comparison between Glaxo and Pasteur StrainsBJU International, 1987